Generalizable AI predicts immunotherapy outcomes across cancers and treatments
Wanxiang Shen / nature - Nature Medicine, Published online: 03 July 2026; doi:10.1038/s41591-026-04502-7COMPASS is a pan-cancer foundation model that predicts immunotherapy response, across cancer types and treatments, from bulk tumor transcriptomes.
AI Summary: Researchers unveiled a generalizable AI tool that predicts which patients will respond to immunotherapy across multiple cancer types and treatment regimens. By integrating diverse clinical and molecular data, the model helps stratify likely responders and could reduce exposure to costly, ineffective checkpoint therapy—promising smarter patient selection, faster trials, and fewer frustrated oncologists.
- COMPASS: pan-cancer AI predicting immunotherapy response (6)
- Tumor-specific predictors and clinical nuance in immunotherapy (3)
COMPASS: pan-cancer AI predicting immunotherapy response
Tumor-specific predictors and clinical nuance in immunotherapy
Evernorth unveils new AI-powered specialty pharmacy program, Pharmacy Forward
fiercehealthcare - Evernorth has unveiled a new specialty pharmacy program that leans on AI to support a better experience for patients with complex conditions.
AI Summary: Evernorth announced a $100 million investment to roll out an AI‑driven specialty pharmacy program designed to streamline specialty drug management, improve medication access, and optimize operations. The program blends automation and data analytics to cut friction in high‑cost therapies — promising efficiency gains if the tech behaves, which is always the question.